JP2019526634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526634A5 JP2019526634A5 JP2019532202A JP2019532202A JP2019526634A5 JP 2019526634 A5 JP2019526634 A5 JP 2019526634A5 JP 2019532202 A JP2019532202 A JP 2019532202A JP 2019532202 A JP2019532202 A JP 2019532202A JP 2019526634 A5 JP2019526634 A5 JP 2019526634A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- aryl
- mitochondrial dysfunction
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 7
- 229920002477 rna polymer Polymers 0.000 claims 5
- 102000053602 DNA Human genes 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 4
- 125000003147 glycosyl group Chemical group 0.000 claims 4
- 239000004593 Epoxy Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical group OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims 2
- 125000003700 epoxy group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- -1 salts compounds Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306094.0 | 2016-08-30 | ||
| EP16306094.0A EP3290039B1 (en) | 2016-08-30 | 2016-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
| PCT/EP2017/071812 WO2018041919A1 (en) | 2016-08-30 | 2017-08-30 | Compounds for treating diseases associated with a mitochondrial dysfonction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526634A JP2019526634A (ja) | 2019-09-19 |
| JP2019526634A5 true JP2019526634A5 (enExample) | 2020-10-01 |
| JP7065854B2 JP7065854B2 (ja) | 2022-05-12 |
Family
ID=56896495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532202A Active JP7065854B2 (ja) | 2016-08-30 | 2017-08-30 | ミトコンドリア機能障害に関連する疾患を治療するための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10857135B2 (enExample) |
| EP (2) | EP3290039B1 (enExample) |
| JP (1) | JP7065854B2 (enExample) |
| KR (1) | KR20200011927A (enExample) |
| CN (1) | CN110035758B (enExample) |
| AU (1) | AU2017317651B2 (enExample) |
| BR (1) | BR112019004236A2 (enExample) |
| CA (1) | CA3034694A1 (enExample) |
| ES (1) | ES2800917T3 (enExample) |
| MA (1) | MA46099A (enExample) |
| MX (1) | MX394782B (enExample) |
| RU (1) | RU2019108824A (enExample) |
| SG (1) | SG11201901689YA (enExample) |
| WO (1) | WO2018041919A1 (enExample) |
| ZA (1) | ZA201900997B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
| US20210052589A1 (en) * | 2018-03-07 | 2021-02-25 | Amabiotics | Compounds for treating alzheimer's disease |
| CA3126424A1 (en) * | 2019-01-29 | 2020-08-06 | Holobiome, Inc. | Methods and compositions for treating and preventing cns disorders and other conditions caused by gut microbial dysbiosis |
| US20230040247A1 (en) * | 2019-09-12 | 2023-02-09 | Amabiotics | Compounds for treating neurodegenerative diseases |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
| CN116850191A (zh) * | 2023-06-16 | 2023-10-10 | 山东大学齐鲁医院 | 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5936615A (ja) * | 1982-08-24 | 1984-02-28 | Takeda Chem Ind Ltd | 発がん予防剤 |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| EP1221615A2 (en) * | 1995-04-25 | 2002-07-10 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| FR3002139B1 (fr) * | 2013-02-21 | 2015-06-19 | Amabiotics | Utilisation cosmetique de la queuine |
| GB201417163D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases |
| GB201417165D0 (en) | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| EP3290039B1 (en) * | 2016-08-30 | 2020-03-25 | Amabiotics | Compounds for treating diseases associated with a mitochondrial dysfonction |
-
2016
- 2016-08-30 EP EP16306094.0A patent/EP3290039B1/en active Active
- 2016-08-30 ES ES16306094T patent/ES2800917T3/es active Active
-
2017
- 2017-08-30 WO PCT/EP2017/071812 patent/WO2018041919A1/en not_active Ceased
- 2017-08-30 AU AU2017317651A patent/AU2017317651B2/en not_active Expired - Fee Related
- 2017-08-30 JP JP2019532202A patent/JP7065854B2/ja active Active
- 2017-08-30 MA MA046099A patent/MA46099A/fr unknown
- 2017-08-30 US US16/328,784 patent/US10857135B2/en active Active
- 2017-08-30 MX MX2019002369A patent/MX394782B/es unknown
- 2017-08-30 EP EP17771680.0A patent/EP3506903A1/en active Pending
- 2017-08-30 RU RU2019108824A patent/RU2019108824A/ru unknown
- 2017-08-30 SG SG11201901689YA patent/SG11201901689YA/en unknown
- 2017-08-30 CN CN201780053445.8A patent/CN110035758B/zh active Active
- 2017-08-30 KR KR1020197008753A patent/KR20200011927A/ko not_active Abandoned
- 2017-08-30 BR BR112019004236A patent/BR112019004236A2/pt not_active IP Right Cessation
- 2017-08-30 CA CA3034694A patent/CA3034694A1/en active Pending
-
2019
- 2019-02-15 ZA ZA2019/00997A patent/ZA201900997B/en unknown
-
2020
- 2020-11-02 US US17/086,583 patent/US11684611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526634A5 (enExample) | ||
| RU2019108824A (ru) | Соединения для лечения заболеваний, связанных с дисфункцией митохондрий | |
| AU2014251087B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| ES2762451T3 (es) | Tratamiento de tumores del sistema nervioso central con coenzima Q10 | |
| US20220000825A1 (en) | Therapeutic compositions | |
| CN106377757B (zh) | 含氧碳氢衍生物作为多粘菌素的协同增效剂的应用 | |
| JP2013532729A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| US20120082720A1 (en) | Compositions For Treating Chronic Viral Infections | |
| JP5113038B2 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
| JP2010522146A5 (enExample) | ||
| BRPI0408918A (pt) | formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo | |
| JP2019513828A5 (enExample) | ||
| JP2005511721A (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
| JP2008543832A (ja) | フルフェナジンおよびその誘導体を含むフェノチアジンのための新しい調合物 | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| KR20120090881A (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물을 포함하는 항암제 조성물 | |
| RU2020132761A (ru) | Соединения для лечения болезни альцгеймера | |
| WO2012096655A1 (en) | Compositions for treating chronic viral infections | |
| US20240139176A1 (en) | Methods of treating or preventing cachexia | |
| JP2019505571A5 (enExample) | ||
| US10702497B2 (en) | Use of acyl-homoserine lactone derivatives as anti-thrombotic agents | |
| JP2025526514A (ja) | 免疫反応調節因子／免疫療法併用システムおよび方法 | |
| JPH02235813A (ja) | 抗腫瘍剤 |